Tag: farnesoid X receptor agonist

1. Obeticholic acid, a farnesoid X receptor agonist, prompts fibrosis improvement in patients with non-alcoholic steatohepatitis (NASH) Evidence Rating Level: 1 (Excellent) Non-alcoholic steatohepatitis (NASH) is an increasingly common cause of chronic liver disease and cirrhosis. Currently, there are no approved treatments for NASH. The farnesoid X receptor, a nuclear receptor, regulates...
1. Obeticholic acid, a farnesoid X receptor agonist, prompts fibrosis improvement in patients with non-alcoholic steatohepatitis (NASH) Evidence Rating Level: 1 (Excellent) Non-alcoholic steatohepatitis (NASH) is an increasingly common cause of chronic liver disease and cirrhosis. Currently, there are no approved treatments for NASH. The farnesoid X receptor, a nuclear receptor, regulates...
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial 1. Obeticholic acid, a farnesoid X receptor agonist, prompts fibrosis improvement in patients with non-alcoholic steatohepatitis (NASH) Evidence Rating Level: 1 (Excellent) Non-alcoholic steatohepatitis (NASH) is an increasingly common cause of chronic liver disease...